Abstract
The Androgen Receptor (AR) is a key molecule in the development, maintenance and progression of prostate cancer (PC). However, the relationship between the AR and co-regulatory proteins that facilitate AR activity in castrate resistant settings remain understudied. Here we show that protein phosphatase 1 regulatory subunits, identified from a phosphatase RNAi screen, direct PP1 catalytic subunits to a varied yet significant response in AR function. As such, we have characterised the PP1ß holoenzyme, myosin phosphatase (MLCP), as a novel ligand independent regulator of the AR. Sustained MLCP activity through down-regulation of the MLCP inhibitory subunit, PPP1R14C, results in impaired AR nuclear translocation, protein stability and transcriptional activity in distinct models of PC progression, culminating in restoration of a non-malignant prostate genotype. Phenotypically, a marked reduction in cell proliferation and migration, characterised by G1 cell cycle arrest is observed, confirming PP1 holoenzyme disruption as a novel treatment approach in PC.
Author supplied keywords
Cite
CITATION STYLE
Grey, J., Jones, D., Wilson, L., Nakjang, S., Clayton, J., Temperley, R., … Robson, C. (2018). Differential regulation of the androgen receptor by protein phosphatase regulatory subunits. Oncotarget, 9(3), 3922–3935. https://doi.org/10.18632/oncotarget.22883
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.